pembrolizumab
merck
['pembro', 'sclc']
exploratory analysis of kn607 at #asco23 do not show any signs that we would ever use the drug in clinical practice. my everlasting take: pembro would be an option in sclc if the trial was not designed to have results faster and try to reach the market.
Husband, Father.
Medical Oncologist and Researcher focused in Thoracic Oncology.
Views are my own.